Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends Hemophilia pact
148.59BUSD
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US7170811035
CUSIP
717081103
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
34.86
PEG Ratio
0.20
Book Value
16.29
Dividend Share
1.67
Dividend Yield
6.56%
Earnings Share
0.76
Wall Street Target Price
31.175
EPS Estimate Current Year
2.929
EPS Estimate Next Year
2.9303
EPS Estimate Current Quarter
0.62
EPS Estimate Next Quarter
0.66
Most Recent Quarter
-
Revenue TTM
59,375,001,600
Gross Profit TTM
41,430,999,040
EBITDA
18,365,999,104
Profit Margin
7.16%
Return On Assets TTM
3.31%
Return On Equity TTM
4.54%
Revenue Per Share TTM
10.493
Qtly Revenue Growth YOY
31.20%
Diluted Eps TTM
0.76
Qtly Earnings Growth YOY
-98.20%
Trailing PE
34.86
Forward PE
8
Price Sales TTM
2.5283
Price Book MRQ
1.6101
Enterprise Value Revenue
3
Enterprise Value EBITDA
14
321.00
3.68%134.98
2.16%78.90
-5.04%728.05
-3.96%98.10
-2.60%288.70
-2.06%171.85
-1.08%36.35
-0.87%66.50
-0.61%147.30
-0.32%Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends Hemophilia pact
Pfizer names oncology chief and company veteran Boshoff as chief scientific officer
Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS
Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company
Pfizer tops earnings estimates, hikes full-year guidance as Covid products help sales - CNBC
FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease - CNBC